MRD Feasibility Study
Trial overview
Minimal Residual Disease monitoring in adult acute lymphoblastic leukaemia: a laboratory feasibility study.
Inclusion criteria
Patients aged between 20 and 60 years inclusive with previously untreated Philadelphia chromosome negative ALL are eligible. Patients should be registered with the Clinical Trials Service Unit (CTSU) and following treatment as defined by the UKALL XII induction protocol.
Exclusion criteria
Patients not following UKALL XII induction therapy.
Contact details
Other trials currently active for Acute Lymphoblastic Leukaemia
Please copy and paste the URL below into a new window for more information on UKALL 2003:
Then go to 'Projects', 'UKALL2003'
A randomized trial for adults with newly diagnosed acute lymphoblastic leukaemia.
For precursor-B lineage ALL, the main aim is to determine if the addition of Rituximab to standard induction chemotherapy results in improved EFS.
For T lineage ALL, the main aim is to determine if the addition of nelarabine following standard induction therapy improves outcomes.
Tags
minimal residual disease acute lymphoblastic leukaemia feasibility study